TFAP2C-DDR1 axis regulates resistance to CDK4/6 inhibitor in breast cancer

Using quantitative high-throughput combination screening and genomics/proteomics approaches, researchers found DDR1 to be a potential driver of resistance to CDK4/6 inhibitors, such as palbociclib. Using this knowledge, they found that DDR1 inhibition combined with palbociclib showed a reduction in resistant tumor growth. They concluded that TFAP2C-DDR1 axis inhibition may be a promising strategy to overcome CDK4/6 resistance.